Skip Ribbon Commands
Skip to main content
Back To Search Results
Dr Lee Yuh Shan

Dr Lee Yuh Shan

​MBBS ( University Malaya ); MRCP ( UK ), FRCPath

Visiting Consultant

Specialty: Haematology

Clinical Interest: Lymphoma

Profile

Education

  • ​MBBS: University of Malaya, 2003
  • MRCP Part 1: UK, 2005
  • MRCP Part 2a: UK, 2006
  • PACES: 2007
  • FRCPath: 2013

Professional Appointments and Committee Memberships

  • Organising committee, World Heart Day 2005 (State level)
  • Organising committee, Introduction to Malignancy and Management for Primary Care 2007

Awards

  • ​SGH Service with a heart award 2016 (Gold)
  • Gold award for Singapore Health Quality Service Award in 2013

Research Interests

Publications

  • Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Mohammed Farooqui, Valdez J, Martyr S, Aue G, Yuh Shan Lee, A Wiestner et al. Lancet Oncology. Lancet Oncol 2015; 16: 169–76.
  • Mycophenolate in the remission induction of a patient with acquired haemophilia A. Yuh Shan Lee, H.J Ng. Haemophlia: Jan 2010; Vol 16, issues 1;180-182. 
  • Surgery associated acquired haemophilia and response to combined rituximab and cyclosporine treatment.  G. Kam, Yuh Shan Lee, T. T. Tan, P. Chow, H. J. Ng. Haemophilia, prepublished online 1st March 2011. 
  • Treatment of advanced stage Hodgkin lymphoma – it's all about risk-benefit. Colin Phipps, Yuh Shan Lee, William Hwang. British Journal of Haematology. October 2012; Volume 159, Issues 1, 113-115 
  • Leukaemic presentation of angioimmunoblastic T-cell lymphoma.  Kenneth Weicong Lin, Yuh Shan Lee and Colin Phipps. BJH. September 2014; Volume 166, Issue 6.
  • Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Daryl Tan, Colin Phipps, Hwang YK, Yuh Shan Lee, WS Kim; YT Goh et al. Lancet Haematology; 2015 Aug;2(8):e326-33  
  • Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Clare Sun, Xin Tian, Yuh Shan Lee, Wiestner A, Aue Get al. Blood. 2015. Nov 5; 126(19):  2213-9. 
  • Interactions between ibrutinib and anti-CD20 antibodies; competing effects on the outcome of combination therapy. Martin Skarzynski, Carsten U Nieman, Yuh Shan Lee, Herman SE, Wiestner A. et al. Clin Cancer Res 2016 Jan 17;22(1):86-95. 
  • Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study. Carsten U. Niemann, Sarah E.M. Herman, Irina Maric, Yuh Shan Lee, Mohammed Z.H. Farooqui and Adrian Wiestner et al. Clin Cancer Res. 2016 Apr 1;22(7):1572-82.
  • Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. Thomas SY Chan, Yuh Shan Lee, Colin Phipps, Eric Tse et al. Oncotarget ;2017; Apr 11; 8(15): 25455–25468.

Research Trials

SingHealth Updates for Healthcare Professionals

HealthXchange E-news Subscription

Health Buddy App

About Us
Patient Care
Research & Innovation
Education & Training
Careers
Giving
SingHealth
SingHealth Duke-NUS

SHP-Head Office, 167 Jalan Bukit Merah Connection One (Tower 5), #15-10, Singapore 150167


© 2024 SingHealth Group. All Rights Reserved.